Short-acting 5-(trifluoromethyl)pyrido[4,3-d]pyrimidin-4(3H)-one derivatives as orally-active calcium-sensing receptor antagonists

Bioorg Med Chem Lett. 2009 Aug 15;19(16):4555-9. doi: 10.1016/j.bmcl.2009.07.004. Epub 2009 Jul 8.

Abstract

Synthesis and structure-activity relationship (SAR) studies on 5-trifluoromethylpyrido[4,3-d]pyrimidin-4(3H)-ones, a novel class of calcium receptor antagonists is described with particular emphasis on optimization of the pharmacokinetic/pharmacodynamic parameters required for a short duration of action compound. Orally-active compounds were identified which displayed the desired animal pharmacology (rapid and transient stimulation of parathyroid hormone) essential for bone anabolic effects.

MeSH terms

  • Administration, Oral
  • Anabolic Agents / administration & dosage
  • Anabolic Agents / chemistry*
  • Anabolic Agents / pharmacokinetics
  • Animals
  • Male
  • Parathyroid Hormone / metabolism
  • Pyrimidinones / administration & dosage
  • Pyrimidinones / chemistry*
  • Pyrimidinones / pharmacokinetics
  • Rats
  • Rats, Sprague-Dawley
  • Receptors, Calcium-Sensing / antagonists & inhibitors*
  • Receptors, Calcium-Sensing / metabolism
  • Structure-Activity Relationship

Substances

  • Anabolic Agents
  • Parathyroid Hormone
  • Pyrimidinones
  • Receptors, Calcium-Sensing